Joyce C Chang1, Cora Sears2, Veronica Torres3, Mary Beth F Son4. 1. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Boston Children's Hospital, Boston, Massachusetts, and Harvard Medical School, Cambridge, Massachusetts. 2. Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 3. Temple University. 4. Boston Children's Hospital and Harvard Medical School.
Abstract
OBJECTIVE: Racial and ethnic minority groups have excess morbidity related to renal disease in pediatric-onset systemic lupus erythematosus (SLE). This study was undertaken to evaluate temporal trends in renal outcomes and racial disparities among hospitalized children with SLE over a period of 14 years. METHODS: We identified patients 21 years old or younger with discharge diagnoses of SLE in the Pediatric Health Information System inpatient database (2006-2019). Adverse renal outcomes included end-stage renal disease (ESRD), dialysis, or transplant, analyzed as a composite and separately. We estimated the odds of adverse renal outcomes at any hospitalization or the first occurrence of an adverse renal outcome, adjusted for calendar period, patient characteristics, and clustering by hospital. We tested whether racial disparities differed by calendar period. RESULTS: There were 20,893 admissions for 7,434 SLE patients, of which 32%, 16%, 12%, and 8% were Black, Hispanic White, Hispanic Other, and Asian, respectively. Proportions of admissions with adverse renal outcomes decreased over time (P < 0.01). Black children remained at the highest risk of adverse renal outcomes at any admission (odds ratio [OR] 2.5 [95% confidence interval (95% CI) 1.8-3.5] versus non-Hispanic White patients). Black and Asian children remained at a higher risk of incident adverse renal outcomes, driven by ESRD among Black children (OR 1.6 [95% CI 1.2-2.1]) and dialysis among Asians (OR 1.7 [95% CI 1.1-2.7]). Relative disparities did not change significantly over time. CONCLUSION: Significant reductions in ESRD and dialysis occurred over time for children with SLE across all racial and ethnic groups. The lack of corresponding reductions in racial disparities highlights the need for targeted interventions to achieve greater treatment benefit among higher risk groups.
OBJECTIVE: Racial and ethnic minority groups have excess morbidity related to renal disease in pediatric-onset systemic lupus erythematosus (SLE). This study was undertaken to evaluate temporal trends in renal outcomes and racial disparities among hospitalized children with SLE over a period of 14 years. METHODS: We identified patients 21 years old or younger with discharge diagnoses of SLE in the Pediatric Health Information System inpatient database (2006-2019). Adverse renal outcomes included end-stage renal disease (ESRD), dialysis, or transplant, analyzed as a composite and separately. We estimated the odds of adverse renal outcomes at any hospitalization or the first occurrence of an adverse renal outcome, adjusted for calendar period, patient characteristics, and clustering by hospital. We tested whether racial disparities differed by calendar period. RESULTS: There were 20,893 admissions for 7,434 SLE patients, of which 32%, 16%, 12%, and 8% were Black, Hispanic White, Hispanic Other, and Asian, respectively. Proportions of admissions with adverse renal outcomes decreased over time (P < 0.01). Black children remained at the highest risk of adverse renal outcomes at any admission (odds ratio [OR] 2.5 [95% confidence interval (95% CI) 1.8-3.5] versus non-Hispanic White patients). Black and Asian children remained at a higher risk of incident adverse renal outcomes, driven by ESRD among Black children (OR 1.6 [95% CI 1.2-2.1]) and dialysis among Asians (OR 1.7 [95% CI 1.1-2.7]). Relative disparities did not change significantly over time. CONCLUSION: Significant reductions in ESRD and dialysis occurred over time for children with SLE across all racial and ethnic groups. The lack of corresponding reductions in racial disparities highlights the need for targeted interventions to achieve greater treatment benefit among higher risk groups.
Authors: Lily Siok Hoon Lim; Eleanor Pullenayegum; Brian M Feldman; Lillian Lim; Dafna D Gladman; Earl D Silverman Journal: Arthritis Care Res (Hoboken) Date: 2018-03-25 Impact factor: 4.794
Authors: Linda T Hiraki; Bing Lu; Steven R Alexander; Tamara Shaykevich; Graciela S Alarcón; Daniel H Solomon; Wolfgang C Winkelmayer; Karen H Costenbader Journal: Arthritis Rheum Date: 2011-07
Authors: Noortje Groot; Nienke de Graeff; Stephen D Marks; Paul Brogan; Tadej Avcin; Brigitte Bader-Meunier; Pavla Dolezalova; Brian M Feldman; Isabelle Kone-Paut; Pekka Lahdenne; Liza McCann; Seza Özen; Clarissa A Pilkington; Angelo Ravelli; Annet van Royen-Kerkhof; Yosef Uziel; Bas J Vastert; Nico M Wulffraat; Michael W Beresford; Sylvia Kamphuis Journal: Ann Rheum Dis Date: 2017-09-06 Impact factor: 19.103
Authors: Sahar Q Khan; Amy Berrington de Gonzalez; Ana F Best; Yingxi Chen; Emily A Haozous; Erik J Rodriquez; Susan Spillane; David A Thomas; Diana Withrow; Neal D Freedman; Meredith S Shiels Journal: JAMA Pediatr Date: 2018-12-03 Impact factor: 16.193